Clinical development of cancer therapeutics that target metabolism

Area of Science:

• Oncology
• Cancer Metabolism
• Biochemistry

Background:

• Cancer cells exhibit elevated glucose and glutamine metabolism compared to normal cells.
• This metabolic reprogramming supports ATP production and provides anabolic precursors for cancer cell survival, growth, and motility.
• Mutant oncogenic proteins and loss of tumor suppressors activate critical metabolic enzymes.

Purpose of the Study:

• To review the rationale for targeting metabolic enzymes as a cancer treatment strategy.
• To detail recent clinical trial results of metabolic inhibitors in advanced cancer patients.

Main Methods:

• Review of pre-clinical studies involving small molecule antagonists of metabolic enzymes in tumor-bearing mice.
• Analysis of clinical trial data from advanced cancer patients treated with metabolic inhibitors.

Main Results:

• Pre-clinical studies demonstrated reasonable therapeutic indices for metabolic enzyme inhibitors.
• Clinical trials are evaluating the efficacy and toxicity of these inhibitors in human patients.

Conclusions:

• Targeting metabolic enzymes is a viable strategy for cancer therapy.
• Metabolic inhibitors show potential for effective cancer treatment with acceptable toxicity profiles.